$0.27
1.10% yesterday
Nasdaq, Jul 16, 10:00 pm CET
ISIN
US00653A1079
Symbol
ADAP
Sector
Industry

Adaptimmune Therapeutics PLC Sponsored ADR Stock price

$0.27
+0.02 6.22% 1M
-0.32 54.24% 6M
-0.27 49.88% YTD
-1.00 78.74% 1Y
-1.45 84.30% 3Y
-8.27 96.84% 5Y
-18.90 98.59% 10Y
-15.73 98.31% 20Y
Nasdaq, Closing price Wed, Jul 16 2025
-0.00 1.10%
ISIN
US00653A1079
Symbol
ADAP
Sector
Industry

Key metrics

Basic
Market capitalization
$72.5m
Enterprise Value
$38.3m
Net debt
positive
Cash
$59.6m
Shares outstanding
1.5b
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.4 | 1.4
EV/Sales
0.2 | 0.7
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
4.8%
Return on Equity
-597.6%
ROCE
-44.0%
ROIC
-66.8%
Debt/Equity
-0.7
Financials (TTM | estimate)
Revenue
$179.6m | $51.4m
EBITDA
$-36.2m | $-113.2m
EBIT
$-47.0m | $-129.2m
Net Income
$-69.9m | $-725.1m
Free Cash Flow
$-111.4m
Growth (TTM | estimate)
Revenue
878.4% | -71.1%
EBITDA
79.4% | -174.9%
EBIT
74.8% | -146.5%
Net Income
57.2% | -924.0%
Free Cash Flow
19.4%
Margin (TTM | estimate)
Gross
5.3%
EBITDA
-20.1% | -220.3%
EBIT
-26.2%
Net
-38.9% | -1,411.1%
Free Cash Flow
-62.0%
More
EPS
$-0.1
FCF per Share
$-0.1
Short interest
2.1%
Employees
506
Rev per Employee
$350.0k
Show more

Is Adaptimmune Therapeutics PLC Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Adaptimmune Therapeutics PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Adaptimmune Therapeutics PLC Sponsored ADR forecast:

8x Buy
57%
5x Hold
36%
1x Sell
7%

Analyst Opinions

14 Analysts have issued a Adaptimmune Therapeutics PLC Sponsored ADR forecast:

Buy
57%
Hold
36%
Sell
7%

Financial data from Adaptimmune Therapeutics PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
180 180
878% 878%
100%
- Direct Costs 0.95 0.95
-
1%
9.56 9.56
-
5%
- Selling and Administrative Expenses 83 83
21% 21%
46%
- Research and Development Expense 143 143
5% 5%
79%
-36 -36
79% 79%
-20%
- Depreciation and Amortization 11 11
0% 0%
6%
EBIT (Operating Income) EBIT -47 -47
75% 75%
-26%
Net Profit -70 -70
57% 57%
-39%

In millions USD.

Don't miss a Thing! We will send you all news about Adaptimmune Therapeutics PLC Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adaptimmune Therapeutics PLC Sponsored ADR Stock News

Neutral
Seeking Alpha
2 months ago
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Cintia Piccina - Chief Commercial Officer Dennis Williams - SVP, Late Stage Development Gavin Wood - CFO John Lunger - VP, Manufacturing Conference Call Participants Marc Frahm - TD Cowen Jonathan Ch...
Neutral
Seeking Alpha
4 months ago
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q4 2024 Earnings Conference Call March 20, 2025 8:00 AM ET Company Participants Juli Miller - IR Adrian Rawcliffe - CEO Cintia Piccina - Chief Commercial Officer Gavin Wood - CFO Dennis Williams - SVP, Late Stage Development John Lunger - VP, Manufacturing and Supply Chain Conference Call Participants Jonathan Chang - Leerink Partners Tony Butler - Ro...

Company Profile

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Head office United Kingdom
CEO Adrian Rawcliffe
Employees 506
Founded 2008
Website www.adaptimmune.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today